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Abstract 
Background: Pairwise and network meta-analyses using fixed effect and random effects models are 
commonly applied to synthesise evidence from randomised controlled trials. The models differ in their 
assumptions and the interpretation of the results. The model choice depends on the objective of the 
analysis and knowledge of the included studies. Fixed effect models are often used because there are 
too few studies with which to estimate the between-study standard deviation from the data alone.  
Objectives: The aim is to propose a framework for eliciting an informative prior distribution for the 
between-study standard deviation in a Bayesian random effects meta-analysis model to genuinely 
represent heterogeneity when data are sparse. 
Methods: We developed an elicitation method using external information such as empirical evidence 
and experts’ beliefs on the ‘range’ of treatment effects in order to infer the prior distribution for the 
between-study standard deviation. We also developed the method to be implemented in R.  
Results: The three-stage elicitation approach allows uncertainty to be represented by a genuine prior 
distribution to avoid making misleading inferences. It is flexible to what judgments an expert can 
provide, and is applicable to all types of outcome measure for which a treatment effect can be 
constructed on an additive scale. 
Conclusions: The choice between using a fixed effect or random effects meta-analysis model 
depends on the inferences required and not on the number of available studies. Our elicitation 
framework captures external evidence about heterogeneity and overcomes the often implausible 
assumption that studies are estimating the same treatment effect, thereby improving the quality of 
inferences in decision making.  
 
Keywords: evidence synthesis, meta-analysis, network meta-analysis, prior elicitation, random 
effects model 
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1 Introduction  
Evidence of clinical effectiveness can arise from multiple sources. Pairwise meta-analysis (MA) is an 
established statistical tool for estimating the relative efficacy of two interventions evaluated in 
randomised controlled trials. In the absence of head-to-head studies, indirect and mixed treatment 
comparison, also known as network meta-analysis (NMA) can be used to synthesise all available 
evidence and make simultaneous comparisons between treatments.  
A pairwise MA and NMA can be conducted using a fixed effect or a random effects model. These 
models differ in their assumptions as well as in the interpretation of the treatment effects (1–4). The 
choice of which model to use depends on the objective of the analysis and knowledge of the included 
studies. In this paper, we investigate the circumstances when and rationale for using these two 
models in National Institute for Health and Care Excellence (NICE) single technology appraisals 
(STAs). We also propose how to overcome the problem of imprecise estimates of the heterogeneity 
parameter in the absence of sufficient sample data.  
A fixed effect model would be appropriate if the objective is to determine whether the treatment had 
an effect in the observed studies (i.e. a conditional inference) and/or would be appropriate when it is 
believed that the true treatment effects in each study are the same. Heterogeneity is expected in MAs 
because they combine studies that have clinical and methodological heterogeneity (5). A random 
effects model would be preferred because it allows for heterogeneity in the treatment effects among 
the studies, and allows the results to be generalised beyond the studies included in the analysis. 
Nevertheless, fixed effect models are still commonly used even when heterogeneity is expected.  
Parameters can be estimated and inferences can be made from either a frequentist or Bayesian 
perspective. The Bayesian approach provides more natural and useful inference, can incorporate 
external information and is deal for problems of decision making. There has been an increase in the 
use of Bayesian evidence synthesis in submissions to NICE, perhaps primarily because the evidence 
synthesis Technical Support Documents (TSDs) issued by the NICE Decision Support Unit (DSU) (6–
11) advocate the Bayesian approach.  
A random effects model requires an estimate of the between-study standard deviation (SD). In the 
case when the number of included studies is small, the estimate of the between-study SD will be 
highly imprecise and biased in a frequentist framework such as using DerSimonian and Laird estimate 
(1). Similarly, a Bayesian analysis of only limited data, using a standard vague /weakly informative 
prior distribution for the between-study SD will give implausible posterior distributions (12). A proper 
Bayesian analysis requires genuine specification of the prior distribution using external evidence, 
typically including experts’ beliefs.  
NICE TSD (7) suggests comparing goodness-of-fit of both fixed effect and random effects models 
using the deviance information criteria (DIC) (13). However, when the number of studies is small, it is 
likely that either model would at least provide an adequate fit to the data, specifically when the data 
4 
 
are not sufficiently informative to learn about the between-study SD. Rather than goodness-of-fit, the 
issue is therefore how best to appropriately represent uncertainty about the treatment effect. When 
heterogeneity is expected, a fixed effect model is likely to be overconfident, and a random effects 
model with a vague prior is likely to be underconfident: a compromise between these two extremes is 
needed, which can be achieved with a more informative prior distribution. 
Higgins et al (1996) (14) presented an example of a Bayesian meta-analysis of meta-analyses to 
create a predictive distribution for the between-study variance in the area of gastroenterology. Other 
authors have generated predicative distributions for  the heterogeneity expected in future MAs in 
more general settings using data from the Cochrane Database of Systematic Reviews for a log odds 
ratio (OR) (15–17), and a standardised mean difference (18). Smith et al (1995) (19) constructed an 
informative prior distribution for the between-study variance using a gamma distribution by assuming 
that odds ratios between studies have roughly one order of magnitude spread, and that it is very 
unlikely that the variability in treatment effects between studies varies by two or more orders of 
magnitude. Spiegelhalter et al (2004) (20) suggested that a half-Normal distribution could be used as 
a prior distribution for the between-study SD and showed how to interpret the prior distribution. NICE 
TSD (8) also suggested using an informative half-Normal prior distribution with mean 0 and variance 
0.322, and provided an interpretation that it represents the belief that 95% of the study-specific ORs lie 
within a factor of 2 from the median OR for each comparison. Both of these half-Normal prior 
distributions are proposed for treatment effects measured by odds ratios. To the best of our 
knowledge, there has been little work on the formal elicitation of experts’ beliefs for the between-study 
SD in random effects MA models. 
To investigate the application of fixed effect and random effects models in submissions to NICE, we 
conducted a review of all of the NICE STAs completed up to 31st October 2016. Results of the review 
are presented in Section 2. In Section 3, we propose novel methods to construct an informative prior 
distribution for the between-study SD utilising external information for all common types of outcome 
measures. Examples of re-analysing two STAs using the proposed elicitation framework are given in 
Section 4. 
2 A review of NICE STAs 
239 NICE STAs were completed between September 2005 (when the STA process was introduced) 
and 31st October 2016. After assessment by SR, a final set of 183 STAs was identified for review. 
Figure 1 presents a flow chart of identification, inclusion and exclusion of STAs.  We have only 
reviewed the original companies’ submissions, and not considered additional analyses that may have 
occurred during the appraisal process.  
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Figure 1: Flow chart showing the identification, inclusion and exclusion of reviews. Abbreviations: STA 
for single technology appraisal, MTA for multiple technology appraisal, RE for random effects, FE for 
fixed effect, MA for meta-analysis and NMA for network meta-analysis, IPD for individual patient-level 
data. *: multiple analyses and analyses for multiple outcomes may have been conducted in one 
submission.  
38 STA submissions used standard pairwise MAs with a single approach being applied within each 
submission: 25 (66%) used a frequentist approach to estimate parameters and make inferences; 8 
239 STAs from 09/2005 to 10/2016  
 28 updated and replaced by MTA, or 
STA, or NICE guidelines 
 26 terminated appraisal due to non-
submissions 
 2 withdrawn 
183 STAs included in the review 
  
 144 STAs with no MA 
 89 STAs with no NMA 
 1 not clear with all relevant 
information were marked as 
confidential 
38 STAs with MA*  
 25 frequentist MA* 
o 10 RE only 
o 7 FE only 
o 11 both 
 8 pooled using IPD 
 5 not report method used 
71 mixed treatment comparisons/NMAs* 
 64 Bayesian NMA* 
o 21 FE only 
o 13 RE only 
o 32 both 
o 4 not report FE or RE model 
 8 frequentist NMA* 
o 2 RE only 
o 3 FE only 
o 2 both 
o 2 not report FE or RE model 
 3 not report method used 
 
93 STAs with NMA*  
 71 mixed treatment comparisons 
 41 indirect comparisons  
 1 not report method used 
 
6 
 
(21%) pooled individual patient-level data across studies; and in 5 cases (13%) it was unclear which 
method was used. 93 STA submissions included NMAs (multiple approaches may have been used in 
one submission). 71 (76%) of these used either a Bayesian or a frequentist NMA, 41 (44%) used 
Bucher indirect comparisons (21) and 1 (1%) didn’t report the method that was used.  
We extracted the rationale for using fixed effect and random effects model for both pairwise MAs and 
NMAs. The findings of the review are presented in Table 1 and are summarised as follows: 
 All of the submissions that performed pairwise MAs used a frequentist approach, and the 
majority of the submissions that performed NMAs used a Bayesian approach (90%). 
 71% of the submissions that performed fixed effect pairwise MAs did not provide a 
justification for the model choice. For the submissions that performed random effects MAs, 60% 
of them gave no justification for the model choice. Fewer submissions used NMAs provided 
no justification for the model choice, 25% and 27% for fixed effect and random effects model, 
respectively. 
 The most frequently stated reason for the use of a fixed effect model was that there were too 
few studies to conduct a random effects model. 
 In some cases, where heterogeneity was noted, there was an acknowledgement that a 
random effects model would be appropriate, although it was not used when there were only 
few studies. 
 Among the pairwise MAs that used a frequentist approach, the choice of fixed effect or 
random effects model was typically assessed using the Q-statistic/𝐼2-statistic. 
 When Bayesian fixed effect and random effects models were both used in a submission, the 
most popular method for choosing the final model was comparing the DIC statistic for the two 
models (62%). 
 Providing either a fixed effect or random effects model within a sensitivity analysis was 
observed in both pairwise MAs (9%) and NMAs (21%) in the case where both models were 
used. 
 Four submissions performed sensitivity analyses using different prior distributions for the 
between-study SD. TA288 (22) considered the possibility of using alternative data sources to 
inform the prior distribution but concluded that no suitable sources were available. TA341 (23) 
used a prior distribution informed using predictive distributions proposed by Turner el al (2012) 
(16). TA173 (24) used a half-Normal prior based on a re-analysis of the data from a previous 
systematic review. TA343 (25) used a half-Normal prior distribution suggested by NICE TSD 
(8). 
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Method used (number of submissions) Justification  N (%) 
Pairwise meta-
analysis (38*) 
Fixed effect model only 
(7) 
No justification 5 (71%) 
Check heterogeneity using test statistic 2 (29%) 
Random effects model 
only (10) 
No justification 6 (60%) 
Allow for heterogeneity 3 (30%) 
Check heterogeneity using test statistic 1 (10%) 
Both models (11**) Not clear which model was a base case 5 (45%) 
Check heterogeneity using test statistic 4 (36%) 
One model as sensitivity analysis 1 (9%) 
Checking inclusion criteria 1 (9%) 
Pooling using individual 
patient-level data (8) 
  
Unclear (5)   
Network meta-
analysis (71*) 
 
Fixed effect model only 
(24) 
Insufficient data 17 (71%) 
No justification 6 (25%) 
Check heterogeneity using test statistic 1 (4%) 
Random effects model 
only (15) 
Allow for heterogeneity 4 (27%) 
No justification 4 (27%) 
Sufficient data 2 (13%) 
Check heterogeneity using test statistic 1 (7%) 
Same model as a previous study 1 (7%) 
Count for correlations 1 (7%) 
Count for multi-arms 1 (7%) 
Unclear  1 (7%) 
Both models (34**) Based on deviance information criteria  21(62%) 
One model as sensitivity analysis 7 (21%) 
Final model fixed effect because of 
insufficient data 
4 (12%) 
Not clear which model was a base case 3 (9%) 
Compare the credible intervals  1 (3%) 
Presence of closed loops 1 (3%) 
 Unclear (2)   
Table 1: Justifications of model choice in submissions. *: multiple analyses and analyses for multiple 
outcomes may have been conducted in one submission. **: multiple reasons for model choice may 
have been used in one analysis.  
Overall, we found that the most frequently stated reason for the use of a fixed effect model was that 
there were too few studies to conduct a random effects model, but not that there was unlikely to be 
heterogeneity or that a conditional inference was of interest. This showed that there is a need for 
more guidance on properly accounting for heterogeneity when the number of included studies is small. 
8 
 
We now present a framework for constructing prior distributions for the heterogeneity parameter using 
external information such as empirical evidence and experts’ beliefs. 
3 General elicitation framework 
For simplicity, we suppose that there is one female expert and the elicitation is conducted by a male 
facilitator. We do not consider issues such as the selection and training of experts, motivation and 
how to elicit a prior distribution from multiple experts, which are covered elsewhere (26–28). The 
general elicitation framework proposed in this section is for performing a pairwise MA. An extension to 
the approach for use in NMAs is discussed later.  
We envisage that the elicitation will take place after specification of the decision problem and 
completion of the systematic literature review, and that this finds that there are few studies that satisfy 
the inclusion/exclusion criteria for the MA. The expert making the judgments could be a clinician, or an 
analyst who conducts the MA. She will be given the information on the decision problem, including 
population, intervention, control and outcome, summary of the included studies, and encouraged to 
think about any potential treatment effect modifiers.  
Suppose that there are 𝑆 studies in the included in the MA, and that the treatment effect in study 𝑖 is 
denoted by 𝛿𝑖, for 𝑖 = 1…𝑆, expressed on some appropriate additive scale. The expert is required to 
make judgements about the likely variability in 𝛿1, … , 𝛿𝑆 between studies. For any two studies 𝑖 and 𝑗, 
one could make judgements about the relative treatment effect 𝛿𝑖/𝛿𝑗, i.e. ‘the treatment effect in one 
study could be 𝑥 times that of the treatment effect in another’. Alternatively, one could consider the 
difference in treatment effects 𝛿𝑖 − 𝛿𝑗 , i.e., ‘the treatment effect in one study could exceed that in 
another study by 𝑥 units’. In this paper, we consider the former case only, building on the discussion 
and analysis by previous authors (19,20). In the latter case, elicitation methods for variances 
discussed in (29) could be considered. 
We assume that 𝛿1, … , 𝛿𝑆 ~𝑁(𝑑, 𝜏
2) , where 𝑑  is the average treatment effect in a population of 
treatment effects and 𝜏2  is the between-study variance, which represents the heterogeneity in 
treatment effects between studies. This is the standard model when 𝛿𝑖 is a log OR, log hazard ratio, or 
mean difference (7). We define 𝑅 to be the ratio of the 97.5th percentile to the 2.5th percentile of 
treatment effects on the natural scale from a population of treatment effects. When the additive 
treatment effect that is estimated in the MA is on the log scale, we propose to elicit the treatment 
effect on the natural scale. For example, if 𝛿𝑖 is a log OR, then we propose using 𝑂𝑅𝑖 in the elicitation, 
which is exp⁡(𝛿𝑖), and 𝑅 = 𝑂𝑅97.5/𝑂𝑅2.5 is the ratio of the 97.5th percentile to the 2.5th percentile of 
ORs in a population of treatment effects, roughly representing the ‘range’ of ORs. Noting that 
log 𝑅 = 𝛿0.975 − 𝛿0.025, we link 𝑅 to 𝜏 via  
𝛿97.5 − 𝛿2.5 = 2 × 1.96𝜏 = 3.92𝜏 
=> log𝑅 =3.92𝜏 
=> 𝜏 =
log(𝑅)
3.92
 (1) 
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We propose asking the expert to make judgements about 𝑅, from which judgements about 𝜏 can be 
inferred using equation (1). However, given the somewhat abstract nature of 𝑅, we suggest providing 
the less formal definition to the expert: she is asked to consider the ratio of the largest to the smallest 
treatment effect on the natural scale that could arise over a set of studies (though the expert should 
be told that ‘largest’ and ‘smallest’ will be interpreted as 97.5th and 2.5th percentiles).  
3.1 A three-stage procedure for eliciting the prior distribution for the between-
study SD 
In some cases, even with adequate training, the expert may find it difficult to make the judgements 
about 𝑅 that are necessary to obtain a distribution for 𝜏. Consequently, we propose a three-stage 
procedure depending on the judgements that the expert is able to make. We firstly present this 
procedure when the treatment effect is a log OR, and then discuss modifications for treatment effects 
reported on different scales. Code for implementing our method using R (31) is available online. 
Instructions are given in Appendix 3. 
3.1.1 Stage 1: confirmation of the need for a random effects model 
The fixed effect model is a special case of the random effects model, corresponding to the judgement 
that 𝑃(𝑅 = 1) = 1, i.e. the expert is certain that the largest OR is the same as the smallest OR in a set 
of studies. The expert is asked to either rule out or accept this case:  
 “Can you be certain that the treatment effects across the studies will be identical, ignoring 
within-study sampling variability?” 
If she is certain that this will be the case, then a fixed effect model should be used with appropriate 
justification provided. Otherwise, we proceed to Stage 2. 
3.1.2 Stage 2: consideration of an upper bound for 𝑅 
If a random effects model is deemed to be appropriate, the expert is then asked if she is able to 
provide an upper bound for 𝑅. She is asked: 
 “Let 𝑅  be the ratio of the largest to the smallest OR. Are you able to judge a maximum 
plausible value for 𝑅? Denoting this limit by 𝑅𝑚𝑎𝑥, this means that you would think values of 𝑅 
above 𝑅𝑚𝑎𝑥 are too implausible to be contemplated.” 
If the expert’s answer for 𝑅𝑚𝑎𝑥 is, for example, 10, this means that she believes that the OR in one 
study could be no more than 10 times that of the OR in another, i.e. one order of magnitude. If the 
expert is not able to provide a value 𝑅𝑚𝑎𝑥, then we recommend using the prior distribution proposed 
by other authors (15–17). For example, Turner et al (2012) (16) proposed a prior distribution for the 
between-study variance in a general setting with the treatment effect measured by a log OR,  
log 𝜏2~𝑁(−2.56,1.742).       (2) 
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If she is able to provide 𝑅𝑚𝑎𝑥, then we proceed to Stage 3. Note that we do not propose asking for a 
lower limit for 𝑅 because we think experts would typically not want to rule out the case 𝑅 = 1 as 
impossible. The expert could also provide a lower limit 𝑅𝑚𝑖𝑛, if she wished, with 𝑅𝑚𝑖𝑛 replacing the 
lower limit of 1 in the following. 
3.1.3 Stage 3: consideration of a full distribution for 𝑅 
We now ask if the expert judges some values in the range [1, 𝑅𝑚𝑎𝑥] to be more likely than others, and 
if she is able to express her beliefs using the roulette elicitation method (30). If she is not able to make 
such judgements, then we propose using prior distributions proposed by (15–17), but now truncated 
to [0, (
log(𝑅𝑚𝑎𝑥)
3.92
)
2
]. 
If she is able to continue with the roulette method, then the range [1, 𝑅𝑚𝑎𝑥] is divided into a number of 
equal-width ‘bins’. The expert is asked to specify her probability of 𝑅 lying in a particular bin by placing 
‘chips’ in that bin, with the proportion of chips allocated representing her probability. The number of 
chips given to the expert is specified by the facilitator. For example, if in total 20 chips are used, then 
each chip represents a probability of 0.05. An illustration is given in Figure 2a. Here, the expert has 
chosen 𝑅𝑚𝑎𝑥 = 10. By placing 5 chips out of 20 in the bin [2, 3], she has expressed a judgement that 
𝑃(2 < 𝑅 ≤ 3) =
5
20
. 
 
  Figure 2a      Figure 2b 
Figure 2: (a) Eliciting beliefs about 𝑅  with the roulette method. (b) The implied distribution of 𝜏 , 
following the elicited judgements about 𝑅 shown in the left hand side Figure 2a. The probabilities of 
‘low’, ‘moderate’ and ‘high’ heterogeneity are in green, yellow and orange, respectively (with negligible 
probability of ‘extreme’ heterogeneity). 
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We suggest fitting either a gamma or lognormal distribution to the elicited probabilities by choosing 
the distribution parameters to minimise the sum of squares between the elicited and fitted cumulative 
probabilities. The R code provided will identify the best fitting distribution out of the gamma and 
lognormal, although there is unlikely to be much difference in the fitted distributions in most practical 
situations. Given that 𝑅 has a lower limit of 1, the package will fit a gamma or lognormal distribution to 
𝑅 − 1. Hence, using a lognormal distribution for example, we will have a prior for 𝜏 specified via 
log(𝑅 − 1)⁡~⁡𝑁(𝑚, 𝑣), 
𝜏 =
log𝑅
3.92
, 
where 𝑚 and 𝑣 are the mean and variance for the elicited lognormal distribution. 
3.2 Feedback 
We propose providing feedback to the expert about the implied distribution of 𝜏, regardless of which 
stage in the above procedure. Spiegelhalter et al (2004) (20) suggested that values of 𝜏 between 0.1 
and 0.5 are considered as reasonable heterogeneity in many contexts (what we describe as 
moderate), from 0.5 to 1.0 as fairly high heterogeneity (what we describe as high) and above 1.0 fairly 
extreme heterogeneity (what we describe as extreme). The probability of 𝜏 in the range of below 0.1, 
(0.1, 0.5), (0.5, 1.0) and above 1.0 will be provided to the expert. The distribution can be displayed 
using a kernel density estimate or histogram of a large sample of randomly generated values of 𝜏. An 
illustration using SHELF package is given in Figure 2b. The probabilities of ‘low’, ‘moderate’ and ‘high’ 
heterogeneity are approximately 0.03, 0.87 and 0.1 respectively (with negligible probability of 
‘extreme’ heterogeneity) given the elicited judgements about 𝑅 in Figure 2a. 
3.3 Other type of outcome measures 
Other scale-free outcome measures include hazard ratio, relative risk and ratio of means for 
continuous outcomes (31,32). The three-stage procedure could be used in these cases, although it is 
less clear that the prior distributions proposed by previous authors (15–17) would be appropriate 
because the distributions were derived based on empirical evidence of heterogeneity in ORs in MAs. 
It is likely that an elicitation exercise of considering a full distribution for the ratio of treatment effects 𝑅, 
for example the ratio of the largest to the smallest hazard ratio among the studies, would be required 
in these cases. 
When the outcome measure is continuous or ordered categorical with the MA model using the identity 
or probit link functions, the expert may find it difficult to express beliefs about the ‘range’ of treatment 
effects because the continuous measurement is not unit-free and the probit scale is difficult to 
interpret directly. We propose using the method described in section 3.1 with the following 
modification: 
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1. Dichotomise the response using some appropriate cut-off 𝑐, to define a new treatment effect 
𝛿𝑖 on the OR scale. 
2. Considering ORs for the dichotomised response, use the three-stage procedure to elicit a 
prior distribution for 𝜏, the variability in log ORs in a population of studies. 
3. Given a prior distribution for 𝜏, convert this to a prior distribution for the between-study SD ?̃?2 
on the original scale (i.e. probit or continuous) via  
?̃? = ωτ,⁡ 
with ω =
√3
π
 for the probit scale, and ω = σ
√3
π
 for the continuous scale, where 𝜎 is an estimate 
of an individual level standard deviation. The estimate could be a summary measure of the 
SDs in the included studies, pooled from included studies, or obtained from a single 
representative study. 
Details of the derivation can be found in Appendix 1.  
3.4 Network meta-analysis 
NMAs typically assume an homogeneous variance model (7,14,33). A similar elicitation method as 
described above can be used to elicit the common heterogeneity parameter in an NMA. We suggest 
asking the expert for the ‘range’ of treatment effects 𝑅 for a pairwise comparison based on the one 
that the expert is most comfortable about in expressing her beliefs. When giving feedback to the 
expert on the probability that the heterogeneity would be low, moderate, high and extremely high, we 
could ask the expert whether she would agree with these elicited probabilities for other pairwise 
comparisons in the network.  
4 Examples: reanalysis of two STAs 
We re-analyse the data from two NICE STAs (TA163 (34) and TA336 (35)) to demonstrate the use of 
our proposed method. BUGS code incorporating the different prior specifications is provided in 
Appendix 2. 
TA163 (34) was a technology appraisal of infliximab for treating acute exacerbations in adults with 
severely active ulcerative colitis. Data were available from 4 studies of 3 treatments (placebo, 
infliximab and ciclosporin) (Figure 3). The outcome measure was the colectomy rate at 3 months. A 
fixed effect model was used in the original submission. Table 2 presents results from a Bayesian NMA 
using a fixed effect model, a random effects model with a vague prior distribution uniform [0, 5], as 
used in Dias et al, (2013) (7) and three alternative informative prior distributions: the prior distribution 
in equation (2), both untruncated and truncated so that 𝑅𝑚𝑎𝑥 ≤ 10, and an elicited prior distribution 
using proposed method in Section 3.The elicited judgements were those of the author’s SR. Results 
are presented as the median with 95% credible and prediction intervals based on 40000 iterations 
from the Markov chain after a burn-in of 60000 iterations using the software OpenBUGS (36). 
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Figure 3: Network diagram for TA163 and TA336 used in the example. The thickness of the line 
represents the number of times pairs of treatment have been compared in studies. Abbreviations: 
Empa for empagliflozin, Lina for linagliptin, Sita for sitagliptin, Saxa for saxagliptin, Can for 
canagliflozin, Met for metformin and SU for sulphonylurea. 
As expected, the DIC statistics for the four models were fairly similar: 34.72, 33.44, 34.70, 35.19 and 
34.60 and did not provide strong support for any one model over the others. The fixed effect model 
showed that there was evidence that ciclosporin reduced the colectomy rate at 3 months relative to 
placebo in the studies included in the NMA, whereas there was insufficient evidence to conclude that 
infliximab had an effect relative to placebo in the included studies. As expected, the results of the 
random effects models demonstrated the sensitivity of the results to the different prior beliefs about 
the heterogeneity parameter. The uniform [0, 5] prior for the heterogeneity parameter was not 
‘updated’ appreciably by the data (Figure 4) and gave very different results compared to the fixed 
effect model (Table 2). There was a large posterior probability, 0.87, that heterogeneity was extremely 
high, equivalent to saying that the probability that the OR in a study could be 50 or more times that of 
the OR in another was 0.87 (The interpretation of the heterogeneity parameter can be found in 
Appendix 1). This is unlikely to be plausible and the results using this prior distribution would not lead 
to reasonable posterior beliefs.  
Results using empirical evidence as prior distribution and elicited prior distributions for the 
heterogeneity were much less uncertain than those produced using the uniform prior distribution but, 
as expected, differed depending on which prior distribution was used (Table 2). Using the untruncated 
lognormal prior, there was a small posterior probability that heterogeneity was extremely high, 0.08. 
The truncated lognormal and elicited prior distributions for the heterogeneity parameter both provided 
zero posterior probability of extreme values for the between-study SD. The truncating eliminated the 
possibility of extreme heterogeneity, i.e. the largest OR in one study could be no more than 10 times 
the OR in another study. The elicited prior distribution can be found in Appendix 3, which resulted in 
TA163 TA336 
Infliximab 
Ciclosporin 
Placebo 
Comparisons 
                2 Empa 25mg+Met+SU 
Empa 10mg+Met+SU 
Lina+Met+SU 
Placebo+Met+SU 
Can 100mg+Met  
Can 300mg+Met 
Comparisons 
                1 
Sita+Met+SU 
Saxa+Met+SU 
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the probability of heterogeneity being low, moderate and high as 0.01, 0.85, and 0.14, respectively. 
The analyses using informative prior distributions for the heterogeneity parameter all suggested that 
ciclosporin reduced the colectomy rate at 3 months compared to placebo based on both the credible 
and prediction intervals, but the effect of infliximab versus placebo was inclusive. The credible and 
predictive intervals in the analyses using empirical evidence and elicited prior distributions were wider 
than the fixed effect interval because of the extra uncertainty but more plausible than analyses based 
on the fixed effect model and random effects model with a uniform prior distribution. 
 
Figure 4: Posterior histogram plot of the between-study standard deviation using prior distribution as 
uniform [0,5]. 
TA336 (35) was a technology appraisal of empagliflozin for the treatment of Type 2 diabetes mellitus 
(T2DM). Data were available from 6 studies of 8 treatments in combination with metformin (Met) or 
metformin and sulphonylurea (Met+SU) (placebo, 10 and 25mg empagaliflozin, linagliptin, sitagliptin, 
saxagliptin, and  100 and 300mg canagliflozin). The outcome measure re-analysed here is the 
change from baseline in body weight for the third line treatment of T2DM at 24 weeks. A fixed effect 
model was used in the original submission. 
Table 2 presents the results of 10mg empagliflozin + Met + SU versus placebo + Met + SU and 
linagliptin + Met + SU as an illustration. The DIC statistics for the four models were again similar: 3.82, 
4.94, 4.61, 5.01 and 4.65. The fixed effect model showed that 10 mg empagliflozin +Met + SU 
reduced the change from baseline in body weight compared to placebo + Met + SU and linagliptin + 
Met + SU. When using the uniform [0, 5] prior distribution for the heterogeneity parameter there was 
more ‘updating’ in this case (Figure 4), but still a large posterior probability, 0.35, that the 
heterogeneity was extremely large. There was a small probability, 0.02, that the heterogeneity was 
extremely large when untrucated lognormal was used as the prior. The truncating eliminated the 
possibility of extreme heterogeneity in treatment effects between studies. The elicited prior can be 
found in Appendix 3, which resulted in the probability of heterogeneity being low, moderate and high 
as 0.06, 0.88, and 0.06, respectively. The analyses using informative prior distributions for the 
heterogeneity parameter all suggested that empagliflzin 10 mg is associated with beneficial treatment 
effect compared to placebo or linagliptin (all in combination with Met and SU) based on the credible 
and prediction intervals, with the exception of the prediction interval using untrucated lognormal prior.   
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Example 1: TA163. Colectomy rate at 3 months: 
treatment effect on log odds ratio scale 
OR, median (95% CrI)  
ciclosporin vs. placebo 
OR , median (95% CrI) 
infliximab vs. placebo 
𝑃𝐿 𝑃𝑀 𝑃𝐻 𝑃𝐸𝐻 
FE 0.13 (0.03, 0.44) 0.72 (0.18, 2.70) 0 0 0 0 
RE with  𝜏𝑂𝑅 ∼ ⁡𝑢𝑛𝑖𝑓𝑜𝑟𝑚⁡[0, 5]  0.02 (0, 1.46) 
0.03 (0, 33.02) 
0.70 (0.01, 84.59) 
0.69 (0, 2498.82) 
0.01 
 
0.05 0.07 0.87 
RE with  𝜏𝑂𝑅
2 ~ log 𝑛𝑜𝑟𝑚𝑎𝑙⁡(0.256, 1.742)  0.11 (0.01, 0.48) 
0.12 (0.01, 0.62) 
0.71 (0.14, 3.25) 
0.71 (0.10, 4.83) 
0.11 
 
0.62 0.18 0.08 
RE with 𝜏𝑂𝑅
2 ~ truncated⁡log 𝑛𝑜𝑟𝑚𝑎𝑙⁡(0.256, 1.742) 𝐼(0, 0.345)  0.12 (0.03, 0.48) 
0.12 (0.03, 0.54) 
0.69 (0.17, 2.77) 
0.69 (0.15, 3.14) 
0.15 
 
0.78 0.07 0 
RE with (𝑅𝑂𝑅 − 1)~⁡𝑔𝑎𝑚𝑚𝑎(2.62, 0.721)  
and 𝜏𝑂𝑅 = log(𝑅𝑂𝑅 + 1) /3.92 
0.12 (0.03, 0.47) 
0.12 (0.02, 0.56) 
0.71 (0.17, 2.97) 
0.71 (0.14, 3.69) 
0.01 0.85 0.14 0 
 
Example 2: TA336. Change from baseline in body weight 
at 24 weeks, kg: treatment effect on mean difference 
scale 
MD, median (95% CrI) 
Empa 10mg+Met+SU 
vs. placebo+Met+SU 
MD, median (95% CrI) 
Empa 10mg+Met+SU 
vs. linagliptin+Met+SU 
𝑃𝐿 𝑃𝑀 𝑃𝐻 𝑃𝐸𝐻 
FE -1.77 (-2.18, -1.35) -2.10 (-2.64, -1.54) 0 0 0 0 
RE with 𝜏𝑀𝐷 ∼ ⁡𝑢𝑛𝑖𝑓𝑜𝑟𝑚⁡[0, 5]  -1.76 (-6.10, 2.70) 
-1.76 (-7.70, 4.38) 
-2.08 (-8.12, 4.08) 
-2.08 (-10.75, 6.55) 
0.14 0.32 0.19 0.35 
RE with 𝜏𝑂𝑅
2 ~ log 𝑛𝑜𝑟𝑚𝑎𝑙⁡(0.256, 1.742)  
and 𝜏𝑀𝐷 = 2.61 × τ𝑂𝑅/1.81 
-1.77 (-2.88, -0.63) 
-1.77 (-3.27, -0.18) 
-2.10 (-3.65, -0.51) 
-2.10 (-4.22, 0.13) 
0.18 0.70 0.10 0.02 
RE with 𝜏𝑂𝑅
2 ~ truncated⁡log 𝑛𝑜𝑟𝑚𝑎𝑙⁡(0.256, 1.742) 𝐼(0, 0.345)  
and 𝜏𝑀𝐷 = 2.61 × τ𝑂𝑅/1.81 
-1.77 (-2.62, -0.93) 
-1.77 (-2.95, -0.63) 
-2.10 (-3.30, -0.93) 
-2.10 (-3.74, -0.46) 
0.21 0.75 0.04 0 
RE with (𝑅𝑂𝑅 − 1)~⁡𝑔𝑎𝑚𝑚𝑎⁡(1.94, 0.741)⁡ 
and 𝜏𝑀𝐷 = 2.61 × log(𝑅𝑂𝑅 + 1) /(3.92 × 1.81) 
-1.78 (-2.76, -0.80) 
-1.77 (-3.11, -0.45) 
-2.10 (-3.47, -0.72) 
-2.10 (-3.98, -0.23) 
0.08 0.88 0.03 0 
Table 2: Comparison of results obtained from fixed effect and random effects models. 𝑃𝐿, 𝑃𝑀, 𝑃𝐻 and 𝑃𝐸𝐻 denote the probability that heterogeneity being low, 
moderate, high and extremely high. Truncated log normal distribution has upper bound 0.345 representing that the ‘range’ of odds ratios between studies 
cannot exceed 10. Results in bold are the predictive distributions of the effects of treatments in a new study. Abbreviations: FE for fixed effect, RE for random 
effects, OR for odds ratio, CrI for credible interval, MD for mean difference, Empa for empagliflozin, Met for metformin and SU for sulphonylurea, vs for versus.
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5 Discussion 
Our review of NICE STAs showed that 17 (71%) out of 24 fixed effect NMAs were chosen on the 
basis that there were too few studies with which to estimate the heterogeneity parameter, but not that 
there was unlikely to be heterogeneity or that a conditional inference was of interest. A consequence 
of this is that decision uncertainty may be underestimated. The choice between using a fixed effect or 
random effects MA model depends on the inferences required and not on the number of studies. 
While a fixed effect model is informative in assessing whether treatments were effective in the 
observed studies, when we expect heterogeneity between studies and want to make unconditional 
inferences and predictions about the treatment effect in a new study, a random effects model should 
be used. 
When heterogeneity is expected, the simple framework we have proposed overcomes the 
inappropriate assumption behind the use of a fixed effect model. We argue that in the absence of 
sufficient sample data, a minimum requirement should be to exclude extreme and implausible values 
from the prior distribution and the common choice of the prior distribution such as uniform [0, 5] or [0, 
2] should not be used. We have shown in the examples that the use of a uniform prior distribution 
when data are sparse would result in implausible estimate for the heterogeneity parameter and 
unreasonable results for the treatment effect.  
Our proposed elicitation framework is flexible with the amount of information an expert is able to 
provide. The minimum information required from the expert is the maximum possible value of the 
‘range’ of treatment effects on the natural scale. For example, if the additive treatment effect is a log 
OR, then the expert is asked whether the OR in one study could be 𝑥 times that of the OR in another 
and what the maximum plausible value of ⁡𝑥  could be. If the expert is not able to provide any 
judgments on the ‘range’ of treatment effects, then empirical evidence such as a prior distribution 
proposed for the heterogeneity expected in future MAs (15–18) could be considered. When the expert 
is able to provide only the maximum value of the ‘range’ of treatment effects, the prior distributions 
proposed by other authors (15–18) should be truncated accordingly before being used in the analysis. 
If the expert is able to provide complete probability judgments, then our proposed framework could 
facilitate the elicitation exercise. 
In terms of presenting the results, we propose reporting the prior and posterior probabilities of 
heterogeneity being low, moderate, high and extremely high rather than simply as the point estimate 
and the credible interval, thereby presenting more information about the consequences of the chosen 
prior distribution. We also advocate the use of prediction intervals for the treatment effects as 
proposed by other authors (2,3,8). Prediction intervals provide a summary of the treatment effect 
expected in a new study which is more relevant to decision making.  
In summary, it is important to incorporate genuine prior information about the heterogeneity parameter 
in a random effects pairwise MA/NMA in the absence of sufficient sample data with which to estimate 
it. Eliciting probability judgments from experts is not straightforward but is important if the aim is to 
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genuinely represent uncertainty in a justifiable and transparent manner to properly inform decision 
making. Our proposed elicitation framework utilises external information such as empirical evidence 
and experts’ beliefs, in which the minimum requirement from the expert is the maximum value of the 
‘range’ of treatment effects. The method also is applicable to all types of outcome measure for which 
a treatment effect can be constructed on an additive scale.  
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Appendix 1 
1 Elicitation method for continuous outcome measures  
For a continuous outcome measure, let 𝑋𝑖𝑗 denote the sample mean in study 𝑖 on treatment arm 𝑗, 
with 𝑗 = 1 the control arm and 𝑗 = 2 the experimental treatment arm. Suppose the sample means 
have the distributions 𝑋𝑖1⁡~⁡𝑁(𝜇𝑖 , 𝜎
2) and 𝑋𝑖2⁡~⁡𝑁(𝜇𝑖 + 𝛽𝑖 , 𝜎
2). Note that in the following, we assume 
the variances 𝜎2 are equal across arms and studies. The treatment effect, mean difference (MD) 𝛽𝑖, is 
on the original scale. A standardised mean difference (SMD), 𝜙𝑖 =
𝛽𝑖
𝜎2
, may be used in meta-analysis if 
the included studies used different scales.  
We further assume that the study-specific treatment effects are normally distributed: 
𝛽1, … , 𝛽𝑆⁡~⁡𝑁(𝑑𝑀𝐷 , 𝜏𝑀𝐷
2 ), or   𝜙1, … , 𝜙𝑆⁡~⁡𝑁(𝑑𝑆𝑀𝐷 , 𝜏𝑆𝑀𝐷
2 ) depending on the scale used in each study. We 
suppose that the expert again prefers to consider variability in treatment effects via ratios of treatment 
effects, and we now consider a modification of the three-stage approach in Section 3.1. 
If we can relate the treatment effects 𝛽𝑖 or 𝜙𝑖 to an odds ratio (OR) 𝛿𝑖, we could derive a distribution 
for 𝜏𝑀𝐷 (the variability in mean differences (MDs) in a population of treatment effects) or 𝜏𝑆𝑀𝐷  (the 
variability in standardised mean differences (SMDs) in a population of treatment effects) via a 
distribution of 𝜏 (the variability in ORs in a population of treatment effects), elicited as before. We 
follow the approach by Chinn (2000) (37), where a continuous response is dichotomised, and a 
normal distribution is approximated by a logistic distribution. 
A cut-off  𝑐 of interest is chosen, and the OR 𝛿𝑖 is defined as 
𝛿𝑖 = (
𝑃(𝑋𝑖2≥𝑐)
𝑃(𝑋𝑖2<𝑐)
) / (
𝑃(𝑋𝑖1≥𝑐)
𝑃(𝑋𝑖1<𝑐)
). (1) 
We can approximate a normal distribution 𝑁(𝑚, 𝑠2) by a logistic distribution with same mean and 
variance, setting the location parameter in the logistic distribution to 𝑚 and the scale parameter to 
𝑠√3
𝜋
. 
Using the logistic distribution approximation, the OR (1) is  
𝛿𝑖 = exp (
𝜙𝑖𝜋
√3
) = exp (
𝛽𝑖𝜋
𝜎√3
) . 
We now have 
𝜏𝑆𝑀𝐷 =
√3𝜏
𝜋
, 
𝜏𝑀𝐷 =
√3𝜎𝜏
𝜋
, 
where 𝜏 is the between-study standard deviation (SD) on the log OR scale. Hence, we can now use 
the method in Section 3.1 with the following modification. 
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1. Dichotomise the response using some appropriate cut-off 𝑐, to define a new treatment effect 
𝛿𝑖: the OR (1). 
2. Considering ORs for the dichotomised response, use the three-stage procedure to elicit a 
prior distribution for 𝜏, the variability in ORs in a population of treatment effects. 
3. Given a prior distribution for 𝜏, convert it to a prior distribution for the between-study SD 𝜏𝑀𝐷  
and 𝜏𝑆𝑀𝐷 ⁡on the continuous scale via 𝜏𝑀𝐷 =
√3𝜎𝜏
𝜋
⁡for MD, and 𝜏𝑆𝑀𝐷 =
√3𝜏
𝜋
 for SMD, where 𝜎 is 
an estimate of an individual level standard deviation. The estimate could be a summary 
measure of the SDs in the included studies, pooled from included studies, or obtained from a 
single representative study. 
2 Elicitation method for ordered categorical data 
For ordered categorical data, the likelihood function for the data would be a multinomial distribution 
with either a logit link function (i.e. a proportional odds model) or a probit link function. Suppose that 
there are 𝐾  outcome categories, denoted by 𝑐1, … , 𝑐𝐾 . Define 𝑃𝑖𝑗𝑘  to be the probability of an 
observation belonging to category 𝑘 or above, on treatment 𝑗 = 1,2, with 𝑗 = 1 the control arm and 
𝑗 = 2 the experimental treatment arm, in study 𝑖. For a logit link function, the treatment effect in the 𝑖th 
study can be defined by a single OR 𝛿𝑖, the OR 
𝑃𝑖2𝑘
1−𝑃𝑖2𝑘
/
𝑃𝑖1𝑘
1−𝑃𝑖1𝑘
 (2) 
which is constant for all 𝑘. Hence, the outcome can be dichotomised into the two category sets 
𝑐1, … , 𝑐𝑘−1 and 𝑐𝑘 , … , 𝑐𝐾, and the elicitation can proceed as in Section 3.1. 
If a probit link function is used, the treatment effect in study 𝑖 may be described by a shift 𝜇𝑖 in the 
mean of the latent normal variable, and we again require a prior distribution for ⁡𝜏⁡̃, the variability in 𝜇𝑖 
in a population of treatment effects. In this case, the OR (2) will change depending on the category 𝑘. 
However, an approximate prior for 𝜏 can be elicited using a similar approach to that in continuous 
outcome measures case: we dichotomise and approximate the latent normal variable by a latent 
logistic variable with scale parameter 
√3
𝜋
. We have the same modification as before: 
1. Dichotomise the response using some appropriate category 𝑐𝑘, and define a new treatment 
effect 𝛿𝑖⁡: the OR (2). 
2. Use the three-stage procedure to elicit a prior distribution for 𝜏, the variability in ORs in a 
population of treatment effects. 
3. Given a prior for 𝜏, convert this to a prior for ⁡𝜏⁡̃ via  
⁡𝜏⁡̃ =
√3
π
𝜏.⁡ 
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The interpretation of the heterogeneity parameter can be found in Table 1.  
Heterogeneity ‘range’ of 
treatment effect, 
𝑅, for scale-free 
outcome measure  
𝜏 for scale-free 
outcome measure 
𝜏 for outcome 
measure using 
probit or 
standardised 
mean difference 
scale 
𝜏 for outcome 
measure using 
mean difference 
scale 
No heterogeneity 1 0 0 0 
Low 1.21 0.05 0.028 0.028𝜎 
Moderate 1.48 0.1 0.06 0.06𝜎 
2.19 0.2 0.11 0.1𝜎 
3.24 0.3 0.17 0.17𝜎 
4.80 0.4 0.22 0.22𝜎 
7.10 0.5 0.28 0.28𝜎 
High 10.51 0.6 0.33 0.33𝜎 
15.55 0.7 0.39 0.39𝜎 
23.01 0.8 0.44 0.44𝜎 
34.06 0.9 0.50 0.50𝜎 
50.40 1.0 0.55 0.55𝜎 
Extremely high 357.81 1.5 0.83 0.83𝜎 
2540.20 2 1.10 1.10𝜎 
Table 1: Suggested interpretation of the between-study standard deviation. The scale-free outcome 
measure refers to odds ratio, relative risk, hazard ratio and ratio of means. The estimate of 𝜎 could be 
a summary measure of the standard deviations in the included studies, pooled from included studies, 
or obtained from a single representative study. 
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Appendix 2 
1 BUGS code for example TA163 
model{                        # *** PROGRAM STARTS 
  for(i in 1:ns){             # LOOP THROUGH STUDIES 
    w[i,1] <- 0               # adjustment for multi-arm trials is zero for control arm 
    delta[i,1] <- 0           # treatment effect is zero for control arm 
    mu[i] ~ dnorm(0,0.0001)          # vague priors for all trial baselines 
    for (k in 1:na[i]) {             # LOOP THROUGH ARMS 
      r[i,k] ~ dbin(p[i,k],n[i,k])   # binomial likelihood 
      logit(p[i,k]) <- mu[i] + delta[i,k]  # model for linear predictor 
      rhat[i,k] <- p[i,k] * n[i,k]   # expected value of the numerators  
      dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))   
                       +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))        #Deviance contribution  } 
       resdev[i] <- sum(dev[i,1:na[i]])       #  summed residual deviance contribution for this trial 
    for (k in 2:na[i]) {             # LOOP THROUGH ARMS 
      # trial-specific LOR distributions 
      delta[i,k] ~ dnorm(md[i,k],precisiond[i,k]) 
      # mean of LOR distributions (with multi-arm trial correction) 
      md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k] 
      # precision of LOR distributions (with multi-arm trial correction) 
      precisiond[i,k] <- precision *2*(k-1)/k 
      # adjustment for multi-arm RCTs 
      w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) 
      sw[i,k] <- sum(w[i,1:k-1])/(k-1)        # cumulative adjustment for multi-arm trials 
    } 
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  }    
  totresdev <- sum(resdev[])           # Total Residual Deviance 
  d[1]<-0       # treatment effect is zero for reference treatment 
  # vague priors for treatment effects 
  for (k in 2:nt){  d[k] ~ dnorm(0,0.0001)  
    OR[k] <- exp(d[k]) 
    d.new[k] ~ dnorm(d[k],precision)  
    OR.new[k] <- exp(d.new[k])  
  } 
  # vague prior U[0,5] for between-trial SD 
  tau ~ dunif(0,5)      
  precision <- pow(tau,-2)   # between-trial precision = (1/between-trial variance) 
  # informative prior using Turner et al (2012) 
  #tau2~dlnorm(-2.57,0.33)   # prior for between study variance from lognormal (-2.57, 1.74^2) 
  #tau<-sqrt(tau2) 
  #precision<-1/tau2       # between-trial precision = (1/between-trial variance) 
  # informative prior using Turner et al (2012) truncated so that the ratio of ORs can't exceed 10 
  #tau2~dlnorm(-2.57,0.33)I(,0.345)   # R=exp(3.92tau)=> tau^2=(log(10)/3.92)^2=0.345 
  #tau<-sqrt(tau2) 
  #precision<-1/tau2       # between-trial precision = (1/between-trial variance) 
  # informative prior using elicitation 
  #R~dgamma(2.68,0.721) #elicited prior for the ‘range’ of OR 
  #tau<-log(R+1)/3.92    #minimum of R is 1; convert the ‘range’ of OR to the between-study standard 
deviation 
  #precision<-pow(tau,-2)       # between-trial precision = (1/between-trial variance) 
}                                    # *** PROGRAM ENDS                     
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#Data (1=placebo, 2=infliximab, 3=ciclosporin) 
list(ns=4,nt=3) 
t[,1]  t[,2] n[,1] r[,1] n[,2] r[,2] na[] 
1 2 21 14 24 7 2  
1 2 3 3 3 0 2  
1 3 9 4 11 3 2  
1 3 15 3 14 3 2  
END 
 
2 BUGS code for example TA336 
model{                               # *** PROGRAM STARTS 
  for(i in 1:ns){                      #   LOOP THROUGH STUDIES 
    w[i,1] <- 0                 # adjustment for multi-arm trials is zero for control arm 
    delta[i,1] <- 0             # treatment effect is zero for control arm 
    mu[i] ~ dnorm(0,0.0001)           # vague priors for all trial baselines 
    for (k in 1:na[i]) {             #  LOOP THROUGH ARMS 
      var[i,k] <- pow(se[i,k],2)   # calculate variances 
      prec[i,k] <- 1/var[i,k]      # set precisions 
      y[i,k] ~ dnorm(theta[i,k],prec[i,k]) # binomial likelihood 
      theta[i,k] <- mu[i] + delta[i,k]  # model for linear predictor 
      dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k]  #Deviance contribution 
    } 
    #  summed residual deviance contribution for this trial 
    resdev[i] <- sum(dev[i,1:na[i]])        
    for (k in 2:na[i]) {             # LOOP THROUGH ARMS 
      # trial-specific distributions 
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      delta[i,k] ~ dnorm(md[i,k],precisiond[i,k]) 
      # mean of distributions, with multi-arm trial correction 
      md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k] 
      # precision of distributions (with multi-arm trial correction) 
      precisiond[i,k] <- precision *2*(k-1)/k 
      # adjustment, multi-arm RCTs 
      w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) 
      # cumulative adjustment for multi-arm trials 
      sw[i,k] <- sum(w[i,1:k-1])/(k-1) 
    } 
  }    
  totresdev <- sum(resdev[])            #Total Residual Deviance 
  d[1]<-0       # treatment effect is zero for control arm 
  d.new[1]<-0 
   # vague priors for treatment effects 
  for (k in 2:nt){  d[k] ~ dnorm(0,0.0001)  
    d.new[k] ~ dnorm(d[k],precision) } 
  # vague prior U[0,5] for between-trial SD 
  tau ~ dunif(0,5)      
  precision <- pow(tau,-2)   # between-trial precision = (1/between-trial variance) 
   # informative prior using Turner et al (2012) on odds ratio scale 
  #tau2~dlnorm(-2.56,0.33)  #odds ratio scale 
  #tau<-sqrt(tau2)/1.81*2.61   #mean difference scale; 2.61 is the mean of individual level standard 
deviation 
  #precision <- pow(tau,-2)   # between-trial precision = (1/between-trial variance) 
28 
 
  # informative prior using Turner et al (2012) truncated so that the ratio of ORs can't exceed 10 on the 
odds ratio scale, R=exp(3.92tau)=>tau^2=(log(10)/3.92)^2=0.345 
  #tau2~dlnorm(-2.56,0.33)I(,0.345)   
  #tau<-sqrt(tau2)/1.81*2.61  #mean difference scale 
  #precision <- pow(tau,-2)   # between-trial precision = (1/between-trial variance) 
  # informative prior using elicitation 
  #R~dgamma(1.94,0.823)        #odds ratio scale 
  #tau<-log(R+1)/3.92/1.81*2.61  #mean difference scale, #minimum of R is 1 
  #precision<-pow(tau,-2)       # between-trial precision = (1/between-trial variance) 
}                                     # *** PROGRAM ENDS      
 
#Data (1=Placebo+Met+SU, 2=Sita+Met+SU, 3=Empa 10mg+Met+SU, 4=Lina+Met+SU, 
5=Saxa+Met+SU, 6=Can 300mg+Met, 7=Can 100mg+Met, 8=Empa 25mg+Met+SU) 
list(ns=6,nt=8) 
t[,1] t[,2] t[,3] y[,1] y[,2] y[,3] se[,1] se[,2] se[,3] na[]  
1 3 8 -0.39 -2.16 -2.39 0.15 0.15 0.16 3  
1 4 NA -0.06 0.27 NA 0.16 0.09 NA 2 
1 2 NA -0.70 0.40 NA 0.3316 0.2551 NA 2 
1 5 NA -0.60 0.20 NA 0.1849 0.1945 NA 2 
2 6 NA 0.2649 -2.384 NA 0.1325 0.1325 NA 2 
1 7 6 -0.648 -1.945 -2.408 0.2362 0.2362 0.2362 3 
END 
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Appendix 3 
1 R code instructions 
A function elicitHeterogen() is available in the development version of the R package SHELF 
(38), which can be installed from GitHub with the commands 
install.packages("devtools") 
devtools::install_github("OakleyJ/SHELF")  
The elicitation tool can then be run using the commands 
library(SHELF) 
elicitHeterogen() 
Type ?elicitHeterogen for further instructions. 
 
2 Elicited prior distribution for the re-analysis of TA163 and TA336 
Table 1 shows the number of bins used and the number of probs/chips allocated in each bin for the 
re-analysis of TA163 and TA336. The elicited prior for 𝑅 − 1 was gamma (2.62, 0.721). It presented 
the beliefs that the probability of heterogeneity being low, moderate and high as 0.01, 0.85, and 0.14, 
respectively. The R function used was elicitHeterogen(lower=1,upper=10,nbins=9).  
The elicited prior for 𝑅 − 1 was gamma (1.94, 0.741). It presented the beliefs that the probability of 
heterogeneity being low, moderate and high as 0.06, 0.88, and 0.06, respectively. The R function 
used was 
elicitHeterogen(lower=1,upper=10,nbins=9,sigma=2.61,scale.free=FALSE). 
Bin boundary [1, 2) [2, 3) [3, 4) [4, 5) [5, 6) [6, 7) [7, 8) [8,9) [9, 10) 
Number of probs 
allocated (TA136) 
4 5 6 6 5 4 2 1 1 
Number of probs 
allocated (TA336) 
4 5 4 3 2 1 1 0 0 
Table 1: The number of bins and the number of probs allocated in each bin for the re-analysis of 
TA163 and TA336. 
 
 
 
